NASDAQ:NAGE Niagen Bioscience (NAGE) Stock Price, News & Analysis $14.13 +0.49 (+3.59%) As of 06/24/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock About Niagen Bioscience Stock (NASDAQ:NAGE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Niagen Bioscience alerts:Sign Up Key Stats Today's Range$13.61▼$14.2250-Day Range$6.40▼$14.1452-Week Range$2.31▼$14.49Volume854,274 shsAverage Volume903,107 shsMarket Capitalization$1.11 billionP/E Ratio83.12Dividend YieldN/APrice Target$19.50Consensus RatingBuy Company OverviewNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Read More… Niagen Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreNAGE MarketRank™: Niagen Bioscience scored higher than 28% of companies evaluated by MarketBeat, and ranked 789th out of 931 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNiagen Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNiagen Bioscience has only been the subject of 2 research reports in the past 90 days.Read more about Niagen Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Niagen Bioscience is 83.12, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.70.Price to Earnings Ratio vs. SectorThe P/E ratio of Niagen Bioscience is 83.12, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.69.Price to Book Value per Share RatioNiagen Bioscience has a P/B Ratio of 23.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for NAGE. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNiagen Bioscience does not currently pay a dividend.Dividend GrowthNiagen Bioscience does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for NAGE. News and Social Media2.3 / 5News Sentiment0.12 News SentimentNiagen Bioscience has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Niagen Bioscience this week, compared to 5 articles on an average week.Search InterestOnly 5 people have searched for NAGE on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat Follows7 people have added Niagen Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Niagen Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.39% of the stock of Niagen Bioscience is held by insiders.Percentage Held by InstitutionsOnly 15.41% of the stock of Niagen Bioscience is held by institutions.Read more about Niagen Bioscience's insider trading history. Receive NAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Niagen Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address NAGE Stock News HeadlinesNiagen Bioscience, Inc. (NAGE) - Yahoo FinanceJune 24 at 5:13 PM | finance.yahoo.comNiagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic TrendsJune 24 at 5:01 PM | seekingalpha.comWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.June 25, 2025 | Crypto Swap Profits (Ad)Even though Niagen Bioscience (NASDAQ:NAGE) has lost US$55m market cap in last 7 days, shareholders are still up 623% over 3 yearsJune 23 at 2:26 PM | finance.yahoo.comNiagen Bioscience (NASDAQ:NAGE) Rating Increased to Strong-Buy at Wall Street ZenJune 22 at 2:15 AM | americanbankingnews.comNiagen Bioscience, Inc: Niagen Bioscience to Participate at the Roth 15th Annual London ConferenceJune 20, 2025 | finanznachrichten.deNiagen Bioscience to Participate at the Roth 15th Annual London ConferenceJune 20, 2025 | businesswire.comNiagen Bioscience (NASDAQ:NAGE) Downgraded to "Buy" Rating by Wall Street ZenJune 15, 2025 | americanbankingnews.comSee More Headlines NAGE Stock Analysis - Frequently Asked Questions How have NAGE shares performed this year? Niagen Bioscience's stock was trading at $5.48 at the start of the year. Since then, NAGE shares have increased by 157.8% and is now trading at $14.13. View the best growth stocks for 2025 here. How do I buy shares of Niagen Bioscience? Shares of NAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/24/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NAGE Previous SymbolNASDAQ:NAGE CIK1386570 WebN/A Phone(310) 388-6706Fax949-419-0294Employees120Year FoundedN/APrice Target and Rating Average Stock Price Target$19.50 High Stock Price Target$23.00 Low Stock Price Target$16.00 Potential Upside/Downside+38.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.17 Trailing P/E Ratio83.12 Forward P/E RatioN/A P/E GrowthN/ANet Income$8.55 million Net Margins13.07% Pretax Margin13.51% Return on Equity19.06% Return on Assets12.20% Debt Debt-to-Equity RatioN/A Current Ratio3.66 Quick Ratio3.12 Sales & Book Value Annual Sales$99.60 million Price / Sales11.17 Cash Flow$0.06 per share Price / Cash Flow227.22 Book Value$0.60 per share Price / Book23.55Miscellaneous Outstanding Shares78,770,000Free Float71,373,000Market Cap$1.11 billion OptionableN/A Beta2.07 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:NAGE) was last updated on 6/25/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Niagen Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Niagen Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.